Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, affect millions of people worldwide and, to date, no definitive cure exists. Many treatments have been tested, but only a few have reached the clinic. To develop more effective and safer therapies, experimental mouse models can provide valuable insights and accelerate research toward new solutions.

Thanks to their ability to reproducibly simulate the pathological mechanisms typical of intestinal inflammation, these models allow us to:

    🧬 – Understand the immunological and molecular basis of IBD

    🧪 – Assess the efficacy and safety of new drug candidates

    🔬 – Explore predictive biomarkers and therapeutic targets

    💉 – Optimize administration strategies and therapeutic combinations

Through the use of validated murine and translational models, it is possible to simulate different phenotypes and stages of the disease, reflecting the clinical heterogeneity observed in patients.

In therapeutic efficacy studies of a drug under development, choosing the most suitable murine model depends on many factors, including the drug’s mechanism of action and cellular target.

Thanks to our team’s expertise, we select the most appropriate preclinical models for your therapeutic goal, ensuring relevant and translatable results for IBD in humans.